Loading…
Loading…
Announcements from Anixa Biosciences, published the moment they cross the wire. Get them by email.
2026
Oct 13, 2026
8:40 AM EDT
Jose Conejo-Garcia, MD, PhD, inventor of Anixa's CAR-T therapy for ovarian cancer, will deliver a keynote presentation at the 2026 Ovarian Cancer Midwest Focus Conference. The conference, hosted by Mayo Clinic and University of Minnesota, will be held November 2–3, 2026, in Rochester, Minnesota.
Oct 05, 2026
8:15 AM EDT
A patient in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer, exhibited stable disease 90 days after treatment. This represents the first such response in Anixa's CAR-T cell therapy trial.
Oct 01, 2026
8:45 AM EDT
The second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. The study is being conducted at Moffitt Cancer Center ("Moffitt").
Sep 21, 2026
8:45 AM EDT
IP Australia has issued Patent Number 2020221280 related to Anixa's breast cancer vaccine technology, exclusively licensed from Cleveland Clinic. This composition-of-matter patent protects the Company's novel approach to breast cancer prevention and treatment in Australia through 2040, addressing a disease for which…
Sep 16, 2026
9:30 AM EDT
The appointment of Carmen Guerra, M.D., M.S.C.E., F.A.C.P., to its Cancer Business Advisory Board.
Sep 09, 2026
8:45 AM EDT
An interview of Chairman and CEO, Dr. Amit Kumar, and breast cancer vaccine clinical trial patient, Sherie Steinberg, will air on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, September 12, at 7:00 PM ET. Bloomberg TV is available in an estimated 73 million homes across the U.S.
Sep 03, 2026
8:00 AM EDT
Dr. Amit Kumar, Chairman and CEO, has been invited to speak at the Nasdaq & LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, at Nasdaq's San Francisco headquarters. Anixa's presentation will be held at 3:40 PM PT with a breakout session to follow.
Aug 24, 2026
9:15 AM EDT
Management will participate in the 2026 Cantor Fitzgerald Global Healthcare Conference being held September 9 – 11, 2026, in New York City.
Aug 18, 2026
8:45 AM EDT
Management will participate in the H.C. Wainwright 28 th Annual Global Investment Conference being held September 14 – 16, 2026.
Jul 14, 2026
8:33 AM EDT
IP Australia has issued a Notice of Acceptance for a new patent related to Anixa's breast cancer vaccine technology.
Jul 06, 2026
8:30 AM EDT
The first patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T/CER-T therapy for recurrent ovarian cancer. The study is being conducted at Moffitt Cancer Center ("Moffitt").
Jun 29, 2026
8:45 AM EDT
The Korean Ministry of Intellectual Property (MOIP) has issued Patent Number 10-2960889 related to Anixa's breast cancer vaccine technology. This composition-of-matter patent, exclusively licensed from Cleveland Clinic, protects the Company's novel approach to breast cancer prevention and treatment in South Korea…
Jun 26, 2026
9:10 AM EDT
Its two clinical-stage immunotherapy programs were presented at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy symposium this week.
Jun 11, 2026
9:05 AM EDT
Two of its clinical-stage immunotherapy programs will be presented at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy symposium, being held June 22 – 23, 2026, at Memorial Sloan Kettering Cancer Center in New York City.
Jun 01, 2026
9:00 AM EDT
The Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.
May 11, 2026
11:48 AM EDT
Updated positive survival observations from its ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, the Company's follicle-stimulating hormone receptor ("FSHR")-targeted CAR-T therapy being developed for the treatment of recurrent ovarian cancer.
May 01, 2026
9:15 AM EDT
An interview of Chairman and CEO, Dr. Amit Kumar, will air on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, May 2, at 7pm ET. Bloomberg TV is available in an estimated 73 million homes across the U.S.
Apr 29, 2026
9:10 AM EDT
The Mexican Institute of Industrial Property (IMPI) has issued Patent Number 432748, covering key aspects of the Company's breast cancer vaccine technology.
Apr 22, 2026
8:45 AM EDT
Cheryl Cox, MHA, Operations Director of the Cell Therapies and Gene Expression Engineering Facility at Moffitt Cancer Center, will be presenting at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, being held May 6 – 9, 2026, in Dublin, Ireland.
Apr 09, 2026
9:05 AM EDT
Dr. Amit Kumar, Anixa's Chairman and CEO, will participate in the upcoming RedChip Biotech Resurgence: Platforms and Pipelines of Today's Innovators virtual investor conference on April 16, 2026, at 3:30 pm ET.
